Going through pressure in generics, Alkem Labs is putting daring bets on orthopaedic implants and biologics. Can its cash-rich core assist this high-risk, high-reward pivot?
Betting past the tablet
Leave a comment
Search
Going through pressure in generics, Alkem Labs is putting daring bets on orthopaedic implants and biologics. Can its cash-rich core assist this high-risk, high-reward pivot?
